Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - urorec
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp152ace144461681a6f02306435b8f1dc
identifier: http://ema.europa.eu/identifier
/EU/1/09/608/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Urorec 4 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-152ace144461681a6f02306435b8f1dc
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/09/608/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - urorec
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Urorec is
Urorec belongs to a group of medicines called alpha1A-adrenoreceptor blockers. Urorec is selective for the receptors located in the prostate, bladder and urethra. By blocking these receptors, it causes smooth muscle in these tissues to relax. This makes it easier for you to pass water and relieves your symptoms.
What Urorec is used for
Urorec is used in adult men to treat the urinary symptoms associated with benign enlargement of the prostate (prostatic hyperplasia), such as:
Do not take Urorec
if you are allergic to silodosin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking Urorec
If you are undergoing eye surgery because of cloudiness of the lens (cataract surgery), it is important that you immediately inform your eye specialist that you are using or have previously used Urorec. This is because some patients treated with this kind of medicine experienced a loss of muscle tone in the iris (the coloured circular part of the eye) during such a surgery. The specialist can take appropriate precautions with respect to medicine and surgical techniques to be used. Ask your doctor whether or not you should postpone or temporarily stop taking Urorec when undergoing cataract surgery.
If you have ever fainted or felt dizzy when suddenly standing up, please inform your doctor before taking Urorec.
Dizziness when standing up and occasionally fainting may occur when taking Urorec, particularly when starting treatment or if you are taking other medicines that lower blood pressure. If this occurs, make sure you sit or lie down straight away until the symptoms have disappeared and inform your doctor as soon as possible (see also section Driving and using machines ).
If you have severe liver problems, you should not take Urorec, as it was not tested in this condition.
If you have problems with your kidneys, please ask your doctor for advice.
If you have moderate kidney problems, your doctor will start Urorec with caution and possibly with a lower dose (see section 3 Dose ).
If you have severe kidney problems, you should not take Urorec.
Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with Urorec. Urorec does not treat prostate cancer.
The treatment with Urorec may lead to an abnormal ejaculation (decrease in the amount of semen released during sex) that may temporarily affect male fertility. This effect disappears after discontinuation of Urorec. Please inform your doctor if you are planning to have children.
Sodium This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially sodium-free .
Children and adolescents
Do not give this medicine to children and adolescents below 18 years since there is no relevant indication for this age group.
Other medicines and Urorec
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Tell your doctor in particular, if you take:
Pregnancy and breast-feeding
Urorec is not intended for use by women.
Fertility
Urorec may reduce the amount of sperm, and so could temporarily affect your ability to father a child. If you are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Do not drive or operate machines if you feel faint, dizzy, drowsy or have blurred vision.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one capsule of Urorec 8 mg per day by oral administration.
Take the capsule always with food, preferably at the same time every day. Do not break or chew the capsule, but swallow it whole, preferably with a glass of water.
Patients with kidney problems
If you have moderate kidney problems, your doctor may prescribe a different dose. For this purpose Urorec 4 mg hard capsules are available.
If you take more Urorec than you should
If you have taken more than one capsule, inform your doctor as soon as possible. If you become dizzy or feel weak, tell your doctor straight away.
If you forget to take Urorec
You may take your capsule later the same day if you have forgotten to take it earlier. If it is almost time for the next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten capsule.
If you stop taking Urorec
If you stop treatment, your symptoms may re-appear.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you notice any of the following allergic reactions: swelling of the face or throat, difficulty in breathing, feeling faint, itchy skin or hives since the consequences could become serious.
The most common side effect is a decrease in the amount of semen released during sex. This effect disappears after discontinuation of Urorec. Please inform your doctor if you are planning to have children.
Dizziness, including dizziness when standing up, and occasionally fainting, may occur.
If you do feel weak or dizzy, make sure you sit or lie down straight away until the symptoms have disappeared. If dizziness when standing up or fainting occurs, please inform your doctor as soon as possible.
Urorec may cause complications during a cataract surgery (eye surgery because of cloudiness of the lens, see section Warnings and precautions ).
It is important that you immediately inform your eye specialist if you are using or have previously used Urorec.
The possible side effects are listed below:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Not known (frequency cannot be estimated from the available data)
If you feel that your sexual life is affected, please tell your doctor.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30 C.
Store in the original package in order to protect from light and moisture.
Do not use this medicine if you notice that is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Urorec contains
Urorec 8 mg The active substance is silodosin. Each capsule contains 8 mg of silodosin.
The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium laurilsulfate, gelatin, titanium dioxide (E171).
Urorec 4 mg The active substance is silodosin. Each capsule contains 4 mg of silodosin.
The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium laurilsulfate, gelatin, titanium dioxide (E171), yellow iron oxide (E172).
What Urorec looks like and contents of the pack
Urorec 8 mg are white, opaque, hard gelatin capsules, size 0 (approximately 21.7 x 7.6 mm).
Urorec 4 mg are yellow, opaque, hard gelatin capsules, size 3 (approximately 15.9 x 5.8 mm).
Urorec is available in packs containing 5, 10, 20, 30, 50, 90, 100 capsules. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Recordati Ireland Ltd. Raheens East Ringaskiddy Co. Cork Ireland
Manufacturer
Recordati Industria Chimica e Farmaceutica S.p.A. Via Matteo Civitali 1 20148 Milan Italy
Laboratoires Bouchara-Recordati Parc M catronic 03410 Saint Victor France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Recordati Ireland Ltd. T l/Tel: + 353 21 4379Lietuva Recordati Polska sp. z o.o.
Tel: +48 22 206 84
Recordati Bulgaria Ltd. .: + 359 2 829 39 Luxembourg/Luxemburg Recordati Ireland Ltd. T l/Tel: + 353 21 4379 esk republika Herbacos Recordati s.r.o. Tel: + 420 466 741 Magyarorsz g Recordati Ireland Ltd. Tel: + 353 21 4379Danmark Recordati Ireland Ltd. Tlf: + 353 21 4379Malta Focused Pharma Ltd. Tel: + 356 79426Deutschland Recordati Pharma GmbH Tel: + 49 731 70Nederland Recordati Ireland Ltd. Tel: + 353 21 4379Eesti Recordati Polska sp. z o.o.
Tel: +48 22 206 84 Norge Recordati Ireland Ltd. Tlf: + 353 21 4379
Recordati Hellas Pharmaceuticals A.E. : + 30 210-6773 sterreich Recordati Austria GmbH Tel: + 43 676 353 0 Espa a Casen Recordati, S.L. Tel: + 34 91 659 15 Polska Recordati Polska sp. z o.o. Tel: + 48 22 206 84 France Laboratoires Bouchara-Recordati T l: + 33 1 45 19 10 Portugal Jaba Recordati, S.A. Tel: + 351 21 432 95 Hrvatska PharmaSwiss d.o.o. Tel: +385 1 63 11 Rom nia Recordati Rom nia S.R.L. Tel: + 40 21 667 17 Ireland Recordati Ireland Ltd. Tel: + 353 21 4379Slovenija Recordati Ireland Ltd. Tel: + 353 21 4379 sland Recordati Ireland Ltd. S mi: + 353 21 4379Slovensk republika Herbacos Recordati s.r.o. Tel: + 420 466 741 Italia Recordati Industria Chimica e Farmaceutica S.p.A. Tel: + 39 02 487Suomi/Finland SwanMedica Oy
Puh/Tel: +358 17 3690
G.C. Papaloisou Ltd. : + 357 22 49 03 Sverige Recordati Ireland Ltd. Tel: + 353 21 4379Latvija Recordati Polska sp. z o.o.
Tel: +48 22 206 84 United Kingdom (Northern Ireland) Recordati Ireland Ltd. Tel: + 353 21 4379This leaflet was last revised in {MM/YYYY}.
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-152ace144461681a6f02306435b8f1dc
Resource Composition:
Generated Narrative: Composition composition-en-152ace144461681a6f02306435b8f1dc
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/09/608/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - urorec
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp152ace144461681a6f02306435b8f1dc
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp152ace144461681a6f02306435b8f1dc
identifier:
http://ema.europa.eu/identifier
/EU/1/09/608/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Urorec 4 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en